The ten largest life-sciences raises took 75.2% of the £2.83 billion deployed into the sector in the first half of 2026, the BioIndustry Association (BIA), the trade body for British life sciences, reported on 10 September in a study written with the accountancy firm Frazier & Deeter1. The median round across the same population came in at £600,000. The mean came in at £8.8 million.
A mean roughly fifteen times the median describes a market with a thin middle: a few enormous raises at the top, a long tail of very small ones, and little in between. The typical British life-sciences company raised enough to run one experiment. The British Business Bank measured the same concentration across the whole equity market last year, when artificial intelligence companies took a record 44% of smaller-business equity value. That market had a fashionable sector to explain it. This one does not, which points at round size rather than subject matter as the driver.
Go further down and the numbers shrink again. The Financial Conduct Authority (the FCA, the UK financial Conduct regulator) published feedback statement FS26/2 on 17 September, a review scoped to business lending of £25,000 or less to sole traders and small partnerships, the only small-business lending inside its consumer-credit perimeter. Within that perimeter it found that 60% of small businesses seeking finance in the past three years sought less than that ceiling2. The median life-sciences round runs twenty-four times higher, and still sits on the same floor of British business finance that most companies stand on.
